Veru INC 10-Q quarterly reports

Veru Inc. reports Q3 2026 results, highlighting progress in enobosarm development and a significant cash position, but also acknowledges substantial doubt regarding its ability to continue as a going concern.

Veru Inc. reports Q2 2026 results, highlighting progress in enobosarm and sabizabulin development, while divesting FC2 business and facing ongoing litigation.

Veru Inc. reported an increased net loss from continuing operations for Q1 2026 but significantly improved its cash position through a public offering, while advancing its enobosarm and sabizabulin drug candidates.

Veru Inc. reports significant net losses and a going concern warning despite positive Phase 2b clinical trial results for enobosarm and strategic pipeline advancements.

Veru Inc. announces positive topline results from its Phase 2b QUALITY clinical study of enobosarm in obese or overweight older patients and provides a financial update in its latest 10-Q filing.

Veru Inc. announces positive Phase 2b clinical trial results for enobosarm in obesity treatment and the sale of its FC2 business, impacting financial results for the quarter ended December 31, 2024.

Veru Inc. announced its Q3 2024 financial results, highlighting a revenue increase and a strategic focus on enobosarm development for obesity and breast cancer.

Veru Inc. reported its financial results for the quarter ended March 31, 2024, highlighting a strategic shift towards enobosarm development and a decrease in overall net revenues.

Veru Inc. reported a net loss of $8.3 million for the quarter ended December 31, 2023, while advancing its enobosarm program and managing its existing FC2 business.